Bioresorbable Coronary Scaffold Promotes Vascular Restoration

A novel bioresorbable coronary scaffold is designed to degrade in about one year, returning the patients’ coronary vessel to its normal de novo state.

The DESolve Novolimus eluting bioresorbable coronary scaffold system is made of proprietary poly-L Lactide (PLLA)-based polymer, providing optimal strength and support to the artery, while delivering the antiproliferative drug Novolimus. Unlike conventional metal stents, the DESolve stent degrades in about one year, leaving behind a thin neointimal lining and well-maintained lumen—similar to a de novo vessel.


Potential additional benefits include a functional endothelium enabling vasomotion and uniform flow dynamics in the vessel.

Among the unique attributes of the DESolve scaffold system are self-apposition to the nominal vessel wall size in cases of malapposition; the ability to maintain radial strength and vessel support for the necessary period of vessel healing while degrading in about a year; and the ability to have a wide margin of expansion. The DESolve scaffold system is a product of Elixir Medical (Sunnyvale, CA, USA), and has received the European Community CE marking of approval.

“Elixir’s DESolve may help to transform the interventional treatment of patients with coronary artery disease by providing optimal vessel support when needed and degrading in about a year, leaving the vessel free of a permanent metallic implant,” said Martin Leon, MD, of New York Presbyterian Hospital / Columbia University Medical Center (New York, NY, USA), and chairman of Elixir Medical’s DESolve Scaffold Program.

“The goal of the interventional cardiologist is to treat and return the patient arteries to their de novo state. We believe the DESolve scaffold makes this goal a reality,” said Motasim Sirhan, CEO of Elixir Medical. “Elixir fulfills its commitment to having the most comprehensive product portfolio of drug-eluting systems spanning all market segments, including the DESyne BD Novolimus Eluting Coronary Stent System (with biodegradable polymer) and the DESyne Novolimus Eluting Coronary Stent System (with durable polymer), providing clinicians with the best choice of customizing patient treatment to achieve optimal clinical outcomes.”

Novolimus is an active metabolite of Sirolimus with antiproliferative and anti-inflammatory properties. Sirolimus is the most widely known mammalian target of rapamycin (mTOR ) macrocyclic lactone inhibitor, used in various treatment applications such as drug eluting stents, transplant, and oncology.

Related Links:
Elixir Medical